Tilburg, 17 September 2024 – Treeway is pleased to announce the successful completion of patient enrollment for the Phase 2A ASURE study. The study is the first randomized, double-blind, placebo-controlled trial aiming to evaluate the safety, pharmacodynamics, and pharmacokinetics of oral edaravone (TW001) in patients with mild-to-moderate Alzheimer’s Disease (AD).
Commenting on this important milestone, Inez de Greef, PhD, CEO Treeway, mentioned:
“This achievement represents a significant step in our ongoing efforts to develop treatments for neurodegenerative diseases like AD. We are hopeful about the potential impact of our lead compound, TW001, in addressing the unmet needs of this condition.”
AD is mainly characterized by the aggregation of beta-amyloid plaques, however other pathophysiological processes such as oxidative stress are emerging as contributors and accelerators of neurodegeneration. Despite the urgent need for effective therapies, many AD clinical trials have faced challenges, highlighting the necessity for new approaches. Treeway’s TW001, an oral formulation of edaravone, has shown promise in preclinical AD models.
Jort Vijverberg MD. PhD., neurologist and principal investigator of the trial, comments: “Reaching this milestone reflects the dedication of the team, of all the sites involved and the participating patients and families. Thank you all! We are eager to analyze the data and continue our efforts towards advancing treatment options.”
The ASURE study aims to share pivotal findings on the primary endpoints including oxidative stress biomarkers and safety, alongside insights into exploratory endpoints such as cognition, EEG and key molecular biomarkers in 2025.
*The ASURE study is funded in part by the Alzheimer Drug Discovery Foundation (ADDF).
For more information, please contact:
Aster van Oordt
Communication Manager
info@treeway.nl
(+31) 135348272